|
Kenneth I Kaitin, Ph.D.
Director
Professor of Medicine
Dr. Kaitin has served as the Director of the Tufts Center for the Study of Drug Development since 1998. He is also a Professor of Medicine at Tufts University School of Medicine. Dr. Kaitin is an internationally recognized expert on the science of drug development. He publishes extensively on the factors that contribute to the slow pace and high cost of pharmaceutical R&D and the impact of regulatory and legislative initiatives to speed new drug development and review. He also testifies in Congress on drug development issues and is frequently quoted in the business and trade press on R&D trends in the research–based pharmaceutical industry. His work covers the entire value chain of pharmaceutical innovation, from discovery to manufacturing and sales and marketing. Dr. Kaitin is a former president of the Drug Information Association and editor–in–chief of the Drug Information Journal. He serves on the Boards of Directors of two public companies and one private company. He received a B.S. from Cornell University and an M.S. and Ph.D. in pharmacology from the University of Rochester.
Contact him by phone at 617–636–2170 or email to kenneth.kaitin@tufts.edu.
Christopher–Paul Milne, D.V.M., M.P.H., J.D.
Associate Director
Formerly a practicing veterinarian in New Jersey and Maryland, Dr. Milne also attended Johns Hopkins University where he earned a master’s degree in public health with a concentration in epidemiology and health statistics. For six years, he worked for the New Jersey Department of Health, initially as a researcher in health risk assessment, later in legislative and regulatory review as Manager of the Public Response Program, and finally as Emergency Response Coordinator. In 1997, Dr. Milne graduated from law school at the Franklin Pierce Law Center in Concord, New Hampshire, where he studied environmental and health law.
Dr. Milne joined the Center in 1998 as a Senior Research Fellow in order to address legal and regulatory issues that affect the research and development of new drugs and biologicals. His current research interests include: challenges to the R&D of new medicines; the role of outsourcing in drug development; incentive programs for pediatric studies; issues related to the R&D of treatments for serious and life–threatening illnesses (fast track diseases), rare disorders and conditions (orphan diseases), and neglected diseases of the developing world; and, trends in FDA and EMEA regulatory and policy initiatives related to the Critical Path Initiative, EMEA Road Map 2010, postmarketing commitments (PMCs), and pharmacogenomic data. Dr. Milne has lectured and published widely on these topics. Dr. Milne is currently Associate Director of the Tufts CSDD and a licensed attorney.
Contact him by phone at 617–636–2188 or email to christopher.milne@tufts.edu.
Joseph A. DiMasi, Ph.D.
Director of Economic Analysis
Dr. DiMasi, who has been with the Tufts Center since the fall of 1987, focuses his research activity on the new drug development and regulatory review processes and the economics of the pharmaceutical industry. His current research examines the impact of policies and practices to speed the development and review processes for new drugs, how firms have organized internally to accommodate the increasing need for pharmacoeconomic studies, the role that pharmacoeconomic evaluations have played in the R&D process, the cost of new drug development, and success and attrition rates for investigational drugs. Dr. DiMasi presents his work at numerous professional and industry conferences in the United States and abroad and has testified before the U.S. Congress in hearings leading up to the FDA Modernization Act of 1997 and reauthorization of the Prescription Drug User Fee Act. Dr. DiMasi received his Ph.D. in economics from Boston College.
Contact him by phone at 617–636–2116 or email to joseph.dimasi@tufts.edu.
Joshua P. Cohen, Ph.D.
Senior Research Fellow
Dr. Cohen investigates public policy issues that relate to prescription drug reimbursement. He joined Tufts CSDD in 1999. His specific areas of research include pharmacy benefits management as it relates to the Medicare prescription drug benefit, formulary standards established by the Centers for Medicare and Medicaid Services to ensure adequate access to prescription drugs for Medicare beneficiaries, comparison of formulary management and pharmacoeconomic assessment in the US and Europe, prescription to over–the–counter switches, and the role of follow–on drugs on the World Health Organization’s Essential Drug List. Prior to joining Tufts CSDD, he completed a post–doctoral fellowship at the Veteran Affairs Medical Center in Philadelphia, while simultaneously serving as a Research Fellow at the University of Pennsylvania’s Leonard Davis Institute for Health Economics. He received his doctoral degree in economics from the University of Amsterdam in 1997.
Contact him by phone at 617–636–3412 or email to joshua.cohen@tufts.edu.
Janice M. Reichert, Ph.D.
Senior Research Fellow
Dr. Reichert has studied innovation in the pharmaceutical and biotechnology industries at the Tufts Center for the Study of Drug Development since 1999. She has published numerous strategic analyses of candidate and approved products, including clinical development and approval times, phase transition probabilities, and approval success rates for new therapeutics and vaccines. Her recent work includes analyses of monoclonal antibodies as cancer therapeutics and as antiviral drugs.
Dr. Reichert has presented her research results as an invited speaker at conferences in the United States, Canada, Europe and China. She is co–chair of the Massachusetts Biotechnology Council’s Clinical Trials Committee and serves on the advisory editorial boards of several journals. In addition, Dr. Reichert regularly provides input to various government, non–profit, and industry organizations.
Dr. Reichert received her Ph.D. in organic chemistry from the University of Pennsylvania and her postdoctoral training as a National Institutes of Health Research Fellow at Harvard Medical School. Before joining the Tufts Center for the Study of Drug Development, Dr. Reichert performed drug discovery research and preclinical development at several companies in the Boston area.
Contact her by phone at 617–636–2182 or email to janice.reichert@tufts.edu.
Kenneth A. Getz, M.B.A.
Senior Research Fellow
Kenneth A. Getz is a senior research fellow at the Tufts CSDD. Considered an expert on the investigative site and CRO markets, R&D management, ECT solutions adoption and clinical research volunteerism, he is a wellknown speaker at conferences, university symposia, and corporate programs and has published extensively in peer review journals and books. Mr. Getz is the founder and chairman of CISCRP, and serves on the Clinical Trials Transformation Initiative board of directors. He is on the editorial boards of the DIA Journal, Controlled Clinical Trials and Research Practitioner and writes a regular column for Applied Clinical Trials. He holds an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and a bachelor's degree, Phi Beta Kappa, from Brandeis University. Mr. Getz worked for over seven years in management consulting, where he assisted biopharmaceutical companies in planning and implementing drug development strategies. He is also the founder and former CEO of CenterWatch.
Contact him by phone at 617–636–3487 or email to kenneth.getz@tufts.edu.
Stella Stergiopoulos, B.A.
Project Manager
Ms. Stergiopoulos is working with Mr. Getz and Ms. Zuckerman on projects involving outsourcing and benchmarking within the pharmaceutical industry. She is also working with Mr. Getz on projects involving R&D management. Ms. Stergiopoulos received her bachelor's degree in Economics from Brandeis University. Before joining Tufts CSDD, she worked at The Brattle Group as a research associate in the finance and utilities practice areas, and she worked at Massachusetts General Hospital researching diabetes.
Contact her by phone at 617–636–0322 or email to stella.stergiopoulos@tufts.edu.
Lanna Feldman, B.A.
Research Analyst
Ms. Feldman assists Dr. DiMasi with updating the Marketed database. In addition, she maintains the EMEA database of all products approved through EMEA's centralized procedure. Ms. Feldman received her bachelor's degree in Psychology from the University of Connecticut. Prior to joining Tufts CSDD, she worked on running clinical trials at Brigham and Women's Hospital.
Contact her by phone at 617–636–2160 or email to lanna.feldman@tufts.edu.
Abraham Seckler, B.S.
Research Analyst
Mr. Seckler works with Mr. Getz and Ms. Zuckerman on projects understanding the preclinical in vivo outsourcing market. He is also working with Dr. Reichert and Ms. Rochon on maintaining the Fast Track Designation database. Mr. Seckler received his bachelor's degree in Neuroscience from The University of Massachusetts at Amherst. Prior to joining Tufts CSDD, he attended the University of Medicine and Dentistry New Jersey's neuroscience program.
Contact him by phone at 617–636–2184 or email to abraham.seckler@tufts.edu.
Andrew Wilson, B.S.
Research Analyst
Mr. Wilson is working with Dr. Milne to examine efforts currently underway to increase pharmaceutical innovation in developing countries. He is also working with Dr. Cohen and Ms. Faden on a project examing formulary decision–making processes. Mr. Wilson received his bachelor's degree in political science and economics from Grand Valley State University in Grand Rapids, MI. Prior to joining Tufts CSDD, he worked as a research assistant at the Community Research Institute at GVSU, interned with the West Michigan Environmental Action Council, and received a research grant to examine physician Medicaid participation in Kent County, MI.
Contact him by phone at 617–636–2785 or email to andrew.wilson@tufts.edu.
Rachael Zuckerman , B.A.
Research Analyst
Ms. Zuckerman works with Mr. Getz on projects understanding the clinical trials outsourcing market. She is also working on a project assessing the impact of mergers and acquisitions on pharmaceutical development. Ms. Zuckerman received her bachelor's degree in mathematics and sociology from Brandeis University. Before joining Tufts CSDD, she worked in tobacco control at the Harvard School of Public Health and the St. Louis University School of Public Health.
Contact her by phone at 617–636–2927 or email to rachael.zuckerman@tufts.edu.
Peg Hewitt, M.S. (L.& I.S.)
Research Librarian
Ms. Hewitt is responsible for information management at Tufts CSDD. She manages the library, the in–house database on drug development issues, and, using a variety of sources, responds to information requests from industry, government, the media, and academic requesters. Ms. Hewitt received an M.S. in library and information science from Drexel University in Philadelphia.
Contact her by phone at 617–636–2185 or email to peg.hewitt@tufts.edu.
|
